基于PD-1的免疫疗法对表皮瘤的疗效受到肠道微生物组的影响
Bertrand Routy1,2,3, Emmanuelle Le Chatelier4, Lisa Derosa1,2,3
1Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
概括
肠道微生物群影响癌症治疗. 特定的细菌如Akkermansia muciniphila可以恢复免疫检查点抑制剂 (PD-1阻断剂) 的有效性.
科学领域:
- 免疫学
- 癌症学
- 微生物组研究
背景情况:
- 针对PD-1/PD-L1轴的免疫检查点抑制剂 (ICI) 对一些癌症患者提供临床益处.
- 对ICI的原发性耐药性是癌症治疗中的一个重大挑战.
- 人们越来越认识到肠道微生物群对ICI有效性的作用.
研究的目的:
- 研究肠道微生物组合对PD-1阻断疗法的原发性耐药性的影响.
- 探索调节肠道微生物组以提高ICI的有效性.
主要方法:
- 在接受ICI治疗的癌症患者中分析肠道微生物组合.
- 在无细菌或接受抗生素治疗的小鼠中使用便微生物移植 (FMT) 的研究.
- 用特定的细菌物种 (Akkermansia muciniphila) 进行口服补充.
- 在小鼠模型中评估抗瘤效应和免疫细胞透.
主要成果:
- 肠道微生物组的异常与ICI的原发性耐药性有关.
- 抗生素治疗减少了ICI的临床益处.
- 接受ICI治疗的患者的FMT恢复了小鼠的抗瘤作用,而没有反应的患者的FMT则没有.
- 与临床反应相关的Akkermansia muciniphila丰度.
- 口服A. muciniphila补充剂恢复了与非响应微生物群结合的小鼠的ICI疗效.
结论:
- 肠道微生物组失调有助于对PD-1封锁的初级抵抗.
- 在调解PD-1阻断的有效性方面,Akkermansia muciniphila发挥着至关重要的作用.
- 调节肠道微生物群,特别是A. muciniphila,是克服ICI耐药性的潜在策略.
相关概念视频
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K


